Rheos Medicines
Biotechnology ResearchMassachusetts, United States11-50 Employees
Rheos Medicines is a Cambridge, Massachusetts-based biopharmaceutical company focused on immunometabolism to develop therapies for immune-mediated diseases. It pursues an advanced, systems-biology program that maps metabolic pathways influencing immune cell behavior and relies on biomarker discovery to support targeted treatment. Founded in 2018 by Third Rock Ventures, the company brings together experts in immunology, metabolism, computational biology, and drug discovery, and it maintains a worldwide collaboration with Roche to identify and advance new therapies for autoimmune and inflammatory conditions. Its target market includes patients affected by autoimmune and inflammatory diseases, with a focus on addressing disease heterogeneity through metabolic signatures that can define subgroups for tailored therapies. The company positions itself at the intersection of biopharmaceutical research and precision medicine, within the immunometabolism and targeted immunology space. A notable development occurred in 2021 when preclinical data indicated potential for MALT1 inhibitors in autoimmune and inflammatory diseases and demonstrated how metabolic biomarkers could accompany patient stratification.
1-888-653-2347 
support@leadiq.com 
